Det går fort til 10 november også. Dette er jo egentlig samme kvalitetsstempel som Ulti fikk i dag på konferansen i Edinburg.
| Presenter: | Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Center, NYC |
|---|---|
| Title: | Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma |
| Date: | 10 November, 2022 |
| Time: | 7pm ET |
Husker da den lå på 10 kr og folk snakket om bull case kr 5000,-
Nei, nå tar du feil - SITC er den høyest aktede konferansen å få dele på, så milevis over melanomakonferansen U deltok på! 
Takk for presiseringen - ja de sa det vel også på forrige Radforsk pod 
For meg virker det mulig at cRNA tar over for peptidvaksiner.
Blir jo en slags genterapi-light. Gleder meg til det kommer mer info. Estimert 14mnd til produkt og da er det klart at de sitter på mer informasjon enn hva som er kommet ut.
Forøvrig helt enig med Profit og henger meg på at innhenting av kapital på dette nivået er usannsynlig. Basert på uttalelser fra EW og gitt kapitalbeholdning og burn-rate.
Det har også blitt gjentatt at dette er siste studien Targovax kjører med oncos, så her er det vinn eller forsvinn.
Tilslutt siterer jeg EW… Verdiene i Targovax ligger i cRNA
Det er ikke veldig lenge til vi får noen svar. De sa på q2 at de ville annonsere noen cRNA resultater innen q4. Vi er allerede på overtid. Det som overrasker meg er at det er så lett å plukke flere hundre K til 1.11-1.12 når vi er så nærme info.
Markedet har ihvertfall ikke trua på noe som helst,anna en kapitainnhenting.
Dagens tema for Ultimovax var at vaksinen UV1 virket godt også i populasjonen med lavt/ingen uttrykk av PD-L1, en av cellereseptorene som CPI’en pembrolizumab (Keytruda) må ha for å hemme en kreftcelle.
Ser man på slide 20 i vedlagte presentasjon så ser man at Oncos-102 aktiverer et annet target for CPI - CTLA4.
Slik jeg tolker det så vil begge metoder (UV1 og Oncos-102) åpne opp tumor slik at de igjen blir sensitive for CPI.
Disse målene for CPI kan utmerket vel bli etablerte biomarkører for hvordan pasienter responderer positivt på kreftbehandling.
Sånn sett blir det spennende å se hva Targo presenterer oralt på SITC - Den viktigste konferansen på sitt felt.
Noen er ute på bunnfiske - og de får napp !!
Skulle ønske det var meg selv, men konto’n er full … dessverre på kurser en god del over dagens nivå, likevel må jeg beholde trua og ikke minst håpet om en viss fugl Fønix … 
Jeg senker mitt kursmål fra 5000-, til 2000,-, rett og slett fordi jeg har flere aksjer nå og SÅ mye penger trenger jeg ikke.
Denne konferansen her ble avlyst i juli, men på fredag så er Thomas Hansen tilbake 
16:00-16:30
Thomas Hansen
VP
Pilot study shows safety, benefit against PD-1-resistant melanoma
A pilot study showed that ONCOS-102, an engineered adenovirus immune stimulant directly injected into cancer cells, plus pembrolizumab (Keytruda®), benefited some patients with melanoma resistant to PD-1 immune checkpoint inhibitors. Led by MSK medical oncologist Alexander Shoushtari, the 21-patient trial to establish safety found the combination treatment was generally well tolerated and showed clinical benefit — including the shrinking or disappearance of tumors in 7 of 20 patients. Additionally, 8 of 15 patients also saw some degree of shrinkage in visible but non-injected tumors. The findings support further investigation in a larger population of patients with longer follow-up, the authors write.
https://newsweb.oslobors.no/message/573458
The ONCOS-102 phase 1b melanoma study is published in the prestigious scientific journal Clinical Cancer Research
· ONCOS-102 in combination with PD-1 checkpoint inhibitor (CPI) Keytruda
demonstrated strong ORR of 35% in PD-1 CPI resistant melanoma, correlating with
robust and persistent immune activation
· A phase 2 trial is under planning, where ONCOS-102 will be tested in a
triple-combination with both PD-1 and CTLA-4 CPIs
Oslo, Norway, 20 October 2022 - Targovax ASA (OSE: TRVX), a clinical-stage
immuno-oncology company developing immune activators to target solid tumors,
today announces that the completed ONCOS-102 phase 1b study in PD-1 CPI
resistant advanced melanoma has been published in the prestigious oncology
journal Clinical Cancer Research, published by the American Association for
Cancer Research (AACR).
PD-1 CPI resistant advanced melanoma is a major unmet medical need affecting up
to 25,000 patients per year in the major markets. The diagnosis is associated
with a poor prognosis and there are currently no approved treatment options
available.
In this phase 1b trial, ONCOS-102 was given intra-tumorally to 21 PD-1 CPI
resistant melanoma patients, followed by re-treatment with the PD-1 CPI
Keytruda. It is anticipated that local injection of ONCOS-102 will induce an
inflammatory immune response in the tumor microenvironment and drive systemic T
-cell activation, which in turn can re-sensitize the patient to PD-1 CPI
therapy.
As expected, ONCOS-102 generated strong and durable immune activation in the
treated patients, which translated into a promising objective response rate
(ORR) of 35%. Importantly, the clinical efficacy was associated with continuous
replication of ONCOS-102 within the tumor, statistically significant increase in
T-cell infiltration, and broad and persistent upregulation of immunological
pathways in responding patients.
Dr. Alexander Shoushtari, Memorial Sloan Kettering Cancer Center, New York said:
“Checkpoint inhibitors have had a significant impact on the way we treat
melanoma; however, a subset of patients still does not respond or become
resistant to treatment. Therefore, there is a high medical need for immune
activating agents to overcome resistance to checkpoint blockade. Although this
was a small study, the 35% ORR and substantial activity in non-injected lesions
is promising, particularly as there is a clear correlation with immunological
biomarker data. We look forward to continuing to work with Targovax in the
upcoming phase 2 trial, which will allow us to validate these findings in a
larger patient cohort as well as to test ONCOS-102 in interesting new
combinations.”
Dr. Lone Ottesen, Chief Medical Officer of Targovax ASA, said: “We are very
happy that our strong ONCOS-102 results in melanoma have been acknowledged by
publication in a high-impact scientific journal. For Targovax, this data set
provides an important clinical proof-of-concept and the translational analyses
have validated and deepened our understanding of the ONCOS-102 mechanism of
action. These findings have allowed us to design a robust phase 2 trial, which
will include combination with the second-generation Fc-enhanced CTLA-4 CPI
botensilimab. CTLA-4 was strongly up-regulated in response to ONCOS-102
treatment in the phase 1b study, and we believe this combination has the
potential to boost response rates up and above 35%, and thereby establish ONCOS
-102 as a leading product candidate in PD-1 resistant melanoma.”
Upcoming phase 2 trial… Med samme tilnærming som i melanom??
Siden det er sagt at melanom er siste Targovax sponsede studie, er det å forvente at andre tar kosten her??
Det hadde vært en kursdrivende melding.
Imponerende av Targo-toget. Innta plassene. Klar for avgang.
Er det noen kloke hoder her som kan si litt om hva som er nytt siden sist.
" with updated publication info"
Polygon og Boblegutten kan sikkert bidra om de har tid og mulighet?
